Breast cancer patients with CD151 overexpression demonstrated a substantially lower OS with a 1.65-fold (P=0.034; HR, 1.65; 95% CI, 1.03–2.59) higher risk of death after adjusting for AJCC stage, breast subtype, and adjuvant chemotherapy (Table 3). This evidence concerns the gene CD151 and breast cancer.